EUVIMEDEUVIMED entdecken
Crossref

2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing

JINWOO LEE, BOYEON KIM, EUNYOUNG SEOL, HEEYONG LEE

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2814-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JINWOO LEE und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Cagrilintide is a long-acting amylin analog developed for obesity and metabolic diseases. Combination therapy with GLP-1 receptor agonists, including semaglutide, has demonstrated enhanced weight reduction through complementary mechanisms compared with GLP-1 monotherapy. Current development strategies rely on weekly administration of each component, typically requiring separate storage and injection. While a once-monthly, long-acting co-formulation could reduce injection burden, improve adherence, and enhance treatment convenience, co-formulation presents physicochemical instability risks including aggregation or precipitation.

Methods

Long-acting Cagri-Sema Injectables were prepared using biodegradable polymers via an emulsion-based microsphere fabrication process. A single-process manufacturing approach was applied to enable simultaneous incorporation of both Cagri-Sema within one production workflow. The pharmacokinetics of Cagri-Sema were evaluated in rats, and plasma concentrations of cagrilintide and semaglutide were maintained for more than 28 days.

Results

Both cagrilintide and semaglutide remained stable when incorporated through the single-process manufacturing approach, with no excessive initial burst release. Stability was also maintained in both co-encapsulated and individually encapsulated microspheres supporting feasibility of combination monthly administration. In rat PK studies of Cagri-Sema microspheres after a single injection, plasma cagrilintide and semaglutide concentration was kept more than 28 days.

Conclusion

The biodegradable microsphere platform enables once-monthly, combination of Cagri-Sema through a single-process manufacturing approach. By reducing injection frequency from weekly dual administration to monthly injection, this strategy may improve treatment convenience and adherence in long-acting combination therapy development for obesity and metabolic disease. Disclosure J. Lee: None. B. Kim: None. E. Seol: None. H. Lee: None.

Zitieren

APA

LEE, J., KIM, B., SEOL, E., & LEE, H. (2026). 2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2814-lb

Vancouver

LEE J, KIM B, SEOL E, LEE H. 2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2814-lb

BibTeX
@article{LEE2026,
  author = {LEE, JINWOO and KIM, BOYEON and SEOL, EUNYOUNG and LEE, HEEYONG},
  title = {2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2814-lb}
}
Kostenlos starten →